Allianz warns nuclear verdicts have almost trebled since 2020
Pharma class actions, mounting PFAS litigation and the growth of collective redress outside the US are creating a challenging market for liability insurers, which are already grappling with “spiralling” claims costs as nuclear verdicts increase in number and size, according to Allianz Commercial.
If you are a subscriber, please sign back in to read this article
If you are not currently a subscriber please see contact details below